Clinical efficacy of weekly cisplatin for treatment of patients with breast cancer

Ying Ma, MMa, Nai-peng Zhang, MMb, Ning An, MMc, Wen-yuan Li, MMd, Wei Zhao, MMe, Yan-cui Liu, MMf,*

Abstract
Background: We will investigate the efficacy and safety of weekly cisplatin (WC) for treatment of patients with breast cancer (BC) systematically.

Methods: This study will describe and critically appraise shared decision approaches used in randomized controlled trials of WC for treatment of patients with BC. We will comprehensively search the following databases: PubMed, EMBASE, Web of Science, Cochrane Library, CINAHL, Allied and Complementary Medicine Database, Wanfang, and Chinese Biomedical Literature Database from inception through July 1, 2019. We will utilize RevMan V.5.3 software (London, UK) for statistical analysis.

Results: This study will systematically explore the efficacy and safety of WC for the treatment of patients with BC through evaluating primary outcomes of overall survival, pathological complete response; and secondary outcomes of cancer-specific survival, recurrence-free survival, disease-free survival, quality of life, and toxicities.

Conclusion: This study will provide latest evidence of WC for the treatment of patients with BC.

Systematic review registration: PROSPERO CRD42019145358.

Abbreviations: BC = breast cancer, RCTs = randomized controlled trials, WC = weekly cisplatin.

Keywords: breast cancer, efficacy, safety, weekly cisplatin

1. Introduction
Breast cancer (BC) is one of the most leading cancers with a high mortality rate.[1–3] Among the 36 most common cancers, BC accounts for 11.6% of all of them.[4–7] It has been reported that BC leads to 6.6% of cancer death in 2018.[8,9] In China, it has been estimated that the rate of BC has increased and associated with the economic status.[10] It has also reported that the incidence rates are 0.034% and 0.017% for urban and rural areas, respectively.[10] In the United States, the cases of BC will reach 268,600 and more than 41,000 patients are predicted to die in 2019.[9] In addition, there are about 3.1 million patients suffering from BC and are receiving treatments.[10]

A variety of clinical studies have reported that weekly cisplatin (WC) has been widely used for the treatment of patients with BC.[11–21] However, its conclusion is still unclear, and no systematic review has assessed the efficacy and safety of WC for BC. Therefore, this study will systematically evaluate the efficacy and safety of WC for the treatment of patients with BC.

2. Methods

2.1. Ethics and dissemination
This study will not inquire ethic approval because we will not use individual patient data. The results of this study are expected to be published at peer-reviewed journals.

2.2. Eligibility criteria for study selection

2.2.1. Type of studies.
All randomized controlled trials (RCTs) will be selected if they focus on assessing the efficacy and safety of WC for the treatment of patients with BC. However, we will exclude studies of nonclinical studies, and non-RCTs.

2.2.2. Type of participants.
Any patients diagnosed with BC will be included regardless the race, age, gender, and economic status.

2.2.3. Type of interventions.
Experimental group: patients received WC monotherapy will be used for inclusion.

Control group: patients received any interventions except any forms of WC will be included.

2.2.4. Type of outcome measurements.
Primary outcomes include overall survival, and pathological complete response.
Secondary outcomes consist of cancer-specific survival; recurrence-free survival; disease-free survival; quality of life, as measured by any related scales; and toxicities.

2.3. Data sources and search strategy

The plan is based on a comprehensively approach to RCTs identification using the following databases: PubMed, EMBASE, Web of Science, Cochrane Library, CINAHL, PsycINFO, Allied and Complementary Medicine Database, Wanfang, and Chinese Biomedical Literature Database from inception through July 1, 2019. Additionally, we will also search dissertations, conference proceedings, and reference lists of included studies. The search strategy for PubMed is showed in Table 1.

| Number | Search terms                                      |
|--------|--------------------------------------------------|
| 1      | Breast cancer                                    |
| 2      | Breast neoplasms                                 |
| 3      | Breast tumor                                     |
| 4      | Or 1–3                                           |
| 5      | Chemotherapy                                     |
| 6      | Cisplatin                                        |
| 7      | Cisplatin                                        |
| 8      | Drug treatment                                   |
| 9      | Drug intervention                                |
| 10     | Drug therapy                                     |
| 11     | Alkylating antineoplastic agent                  |
| 12     | Or 5–11                                          |
| 13     | Randomized controlled trials                     |
| 14     | Randomly                                         |
| 15     | Blinding                                         |
| 16     | Concealment                                      |
| 17     | Control                                          |
| 18     | Comparator                                       |
| 19     | Study                                            |
| 20     | Or 13–19                                        |
| 21     | 4 and 12 and 20                                  |

Table 1

Search strategy for PubMed.

2.4. Data collection and management

2.4.1. Study selection. Two authors will independently scan all titles and abstracts identified from the search strategy for all databases. All duplicated and irrelevant studies will be excluded. Any discrepancies between 2 authors will be solved by a third author via discussion. Full reports will be further obtained for all remaining studies to judge whether they meet the final eligibility criteria. The results of study selection will be presented in the flowchart.

2.4.2. Data extraction. Two authors will carry out data extraction using a standardized data extraction table to collect relevant data from each eligible trial. The data comprises of publication details, study characteristics, study setting, study design, sample size, patient characteristics, diagnostic criteria, eligibility criteria, experimental and control details, outcome measurements, safety, and follow-up information. Any divergences regarding data extraction between 2 authors will be solved by a third author via discussion. If there is insufficient or missing information, we will contact corresponding authors of primary RCTs. If we cannot receive those data, we will just analyze available data. Moreover, we will discuss its possible impacts in the text.

2.5. Risk of bias assessment for eligible studies

In this study, risk of bias for all eligible studies will be assessed using Cochrane risk of bias tool. This tool has 7 aspects and each aspect is judged as 3 levels: high risk of bias, unclear risk of bias, and low risk of bias. Two authors will independently perform risk of bias for all included studies. All different opinions between 2 authors will be solved by a third author through discussion.

2.6. Treatment effect measurements

For continuous outcomes, mean differences or standardized mean differences with 95% confidence intervals will be exerted. For dichotomous outcomes, risk ratios or odds ratios with 95% confidence intervals will be calculated.

2.7. Statistical analysis

We will use RevMan V.5.3 software (London, UK) for statistical analysis in this study. We will use $I^2$ statistic test to identify heterogeneity among eligible studies. Values of $I^2 \leq 50\%$ exert low heterogeneity, and a fixed-effect model will be used. In addition, meta-analysis will be carried out. On the other hand, values of $I^2 > 50\%$ mean significant heterogeneity, and a random-effect model will be applied. Under such situation, we will perform subgroup analysis to explore any factors of such high heterogeneity. We will report outcome results as a narrative summary if substantial heterogeneity still exerts after subgroup analysis.

Subgroup analysis will be performed based on the different treatments, controls, and outcomes. Sensitivity analysis will also be carried out by removing studies with high risk of bias. Finally, we will investigate the reporting bias if sufficient trials are entered using funnel plots and Egger linear regression test.

3. Discussion

BC is one of most common cancers in female population. WC has been widely used clinically to treat this disorder. Currently, there is limited evidence to determine whether WC has similar effect on patients with BC. Therefore, the comparisons of the efficacy and safety will be investigated between WC and other interventions in the experimental group and control group. This study will provide high-quality evidence-based medicine to determine whether WC is an effective and safety treatment for patients with BC.

Author contributions

Conceptualization: Ying Ma, Ning An, Yan-cui Liu.
Data curation: Ying Ma, Nai-peng Zhang, Wen-yuan Li, Wei Zhao, Yan-cui Liu.
Formal analysis: Ying Ma, Nai-peng Zhang, Ning An, Wen-yuan Li, Wei Zhao.
Funding acquisition: Yan-cui Liu.
Investigation: Yan-cui Liu.
Methodology: Nai-peng Zhang, Ning An, Wen-yuan Li, Wei Zhao.
Project administration: Ning An, Yan-cui Liu.
Resources: Nai-peng Zhang, Ning An, Wen-yuan Li, Wei Zhao, Yan-cui Liu.
Software: Ying Ma, Nai-peng Zhang, Ning An, Wen-yuan Li, Wei Zhao.
Supervision: Ying Ma, Yan-cui Liu.
Validation: Ying Ma, Nai-peng Zhang, Ning An, Wen-yuan Li, Wei Zhao.
Visualization: Nai-peng Zhang, Wen-yuan Li, Wei Zhao.
Writing – original draft: Ying Ma, Nai-peng Zhang, Ning An, Wen-yuan Li, Wei Zhao, Yan-cui Liu.
Writing – review & editing: Ying Ma, Nai-peng Zhang, Ning An, Wen-yuan Li, Wei Zhao, Yan-cui Liu.

References

[1] Armstrong N, Ryder S, Forbes C, et al. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol 2019;11:543–61.
[2] Strober JW, Brady MJ. Dietary fructose consumption and triple-negative breast cancer incidence. Front Endocrinol (Lausanne) 2019;10:367.
[3] Polevarzadeh M, Aminshahi M, Afsargharehbagh R, et al. Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat 2019;176:519–33.
[4] Momenimovahed Z, Salehiniya H. Epidemiological characteristics of breast cancer incidence. Front Endocrinol (Lausanne) 2019;10:367.
[5] Wendt C, Margolin S. Identifying breast cancer susceptibility genes: a review of the genetic background in familial breast cancer. Acta Oncol 2019;58:135–46.
[6] Husain M, Nolan TS, Foy K, et al. An overview of the unique challenges facing African-American breast cancer survivors. Support Care Cancer 2019;27:729–43.
[7] Beckwit CH, Bruskay A, Olvai ZN, Wells A. Statin drugs to reduce breast cancer recurrence and mortality. Breast Cancer Res Treat 2018;20:144.
[8] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 2018;68:394–424.
[9] Fan L, Strasser-Weippl K, Li JI, et al. Breast cancer in China. Lancet Oncol 2014;15:e279–89.
[10] Frasci G, D’Auito G, Comella P, et al. A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study. Ann Oncol 2005;16:1268–73.
[11] Sánchez-Escrivá Morcuende R, Alés-Martínez JE, Aramburo González PM. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens. Clin Transl Oncol 2007;9:549–64.
[12] Torrisi R, Balduzzi A, Ghisini R, et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and intravenous fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 2008;62:667–72.
[13] Huang XE, Li CG, Li Y, et al. Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev 2011;12:2797–800.
[14] Sánchez-Escribano Morcuende R, Alés-Martínez JE, Aramburo González PM. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens. Clin Transl Oncol 2007;9:549–64.
[15] Frasci G, D’Auito G, Comella P, et al. Southern Italy Cooperative Oncology Group, Italy: Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) weekly combination in Chinese breast cancer patients. BMC Cancer 2013;13:232.
[16] Frasci G, Comella P, Rinaldo M, et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer: final analysis of a sicog phase III study. Br J Cancer 2006;95:1005–12.
[17] Frasci G, D’Auito G, Comella P, et al. Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908. Ann Oncol 2010;21:707–16.
[18] Frasci G, Comella P, Rinaldo M, et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. Ann Oncol 2005;16:1268–73.
[19] Frasci G, D’Auito G, Comella P, et al. Southern Italy Cooperative Oncology Group (SICOG) Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs twice weekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study. Br J Cancer 2006;95:1005–12.
[20] Frasci G, D’Auito G, Comella P, et al. Southern Italy Cooperative Oncology Group (SICOG) Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs twice weekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study. Br J Cancer 2006;95:1005–12.
[21] Donadio M, Ardine M, Berruti A, et al. Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes. Oncology 2005;69:408–13.